CS
MAZE

Candriam SCA’s Maze Therapeutics MAZE Stock Holding History

Candriam SCA’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Sell
273,932
-4,235
-2% -$111K 0.04% 310
2026
Q1 		$8.3M Buy
+278,167
New +$12.3M 0.04% 307

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Candriam SCA's MAZE Position: Q2 2026 in Review

Candriam SCA reduced its Maze Therapeutics (MAZE) stake by 1.5% in Q2 2026, selling an estimated $111K and leaving 273,932 shares worth $8.17M. The position accounts for 0.04% of the portfolio, ranked #310.

Candriam SCA first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.3M in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Candriam SCA held 273,932 shares of Maze Therapeutics worth $8.17M as of Q2 2026.
  • Candriam SCA sold 4,235 Maze Therapeutics shares in Q2 2026, an estimated $111K.
  • Maze Therapeutics made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #310 holding.
  • Candriam SCA first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Candriam SCA's Maze Therapeutics position peaked at $8.3M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.